This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Fpmp-Protected α -Hydroxyphosphonate Diesters for The Synthesis of Pro-Oligonucleotides

Ralf P. Mauritz^a; Chris Meier^a

^a Johann Wolfgang Goethe-University, Institute of Organic Chemistry, Frankfurt, Germany

To cite this Article Mauritz, Ralf P. and Meier, Chris(1997) 'Fpmp-Protected α -Hydroxyphosphonate Diesters for The Synthesis of Pro-Oligonucleotides', Nucleosides, Nucleotides and Nucleic Acids, 16: 5, 675 — 678

To link to this Article: DOI: 10.1080/07328319708002933 URL: http://dx.doi.org/10.1080/07328319708002933

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

FPMP-PROTECTED α-HYDROXYPHOSPHONATE DIESTERS FOR THE SYNTHESIS OF PRO-OLIGONUCLEOTIDES

Ralf P. Mauritz and Chris Meier*

Institute of Organic Chemistry, Johann Wolfgang Goethe-University, Marie-Curie-Str.11, D-60439 Frankfurt am Main, Germany

ABSTRACT: The synthesis of Fpmp-protected α -hydroxybenzylphosphonate diesters as building blocks for the oligonucleotide synthesis is described. The modified oligonucleotides obtained after cleavage from the solid support and deprotection of the acid-labile Fpmp group should lead to potential *pro-oligonucleotides*.

Antisense oligonucleotides on the basis of DNA or RNA have become an important possibility to treat viral diseases¹. The mode of action is the hybridization of an antisense oligonucleotide with a complementary sequence of the sense-RNA target strand. Beside the selective recognition of their target, oligonucleotides have to be taken up by cells and have to be nuclease-resistant. Natural oligonucleotides showed no biological activity because of low penetration through biomembranes and high instability against cellular endo- and exonucleases. Methylphosphonate-, phosphorothioate-, phosphorodithioate- and phosphotriester-modified oligonucleotides have been synthesized to circumvent these limitations². These modifications are more lipophilic than natural phosphodiester oligonucleotides and more stable against nucleases. But most of them are not degradable which is not always desired because of toxic side effects. The consequence for this purpose is the use of *pro-oligonucleotides*³.

In previous studies, we presented the α -hydroxybenzylphosphonate moiety as a new lipophilic phosphodiester-backbone modification, which could additionally act as a **pro-oligonucleotide-concept**⁴. It was shown, that α -hydroxybenzylphosphonates bearing strong electron-withdrawing substituents in the aromatic ring rearrange into the corresponding benzylphosphotriesters⁵. On the other hand, introduction of an electron-donating substituent resulted the direct cleavage reaction. Therefore we decided to synthesize two different derivatives of dimer building blocks: one dimer contains a α -hydroxy-2-nitrobenzyl residue (predominantly rearrangement) whereas the second is the unsubstituted α -hydroxybenzyl moiety (exclusively direct cleavage). In our earlier work, we used different silyl-protected α -hydroxyphosphonates as building blocks for the synthesis of (T)15-oligonucleotides⁴. To

676 MAURITZ AND MEIER

cleave the oligomers from the solid support, we used a cold saturated solution of ammonia in dry methanol within 5 min. This method is suitable for the preparation of polythymidine oligonucleotides, but unlikely to synthesize mixed oligonucleotides because we have to use aqueous ammonia to cleave the base-protecting groups if we use the standard amidites for oligonucleotide synthesis (dA^{bz}, dG^{ibu}) and dC^{bz} . Herein we make use of the 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) group, which was first introduced by Reese for the protection of 2'-hydroxy functions in oligoribonucleotide synthesis⁶. Using this acidlabile group, α -hydroxyphosphonate modified oligonucleotides should be cleaved still Fpmp-protected from the solid support by aqueous ammonia. After desalting and purification, the Fpmp unblocked oligonucleotides can be isolated after treatment with a solution of 0.01M hydrochloric acid at pH 2.0-2.5 or with a solution of sodium acetate at pH 3.25 as described by Rao⁷. Under these acidic conditions, no cleavage or rearrangement of the α -hydroxyphosphonate moiety occurs. The Fpmp-protected dimer building blocks were prepared as 3'-oxalyl-linked to the AP-CPG-support 1 and as 3'-phosphoamidites 2.

The syntheses of 1 and 2 are shown in scheme 1. The syntheses start from thymidyl-3'-H-phosphonate 3 which was coupled with 3'-O-t-butyldiphenylsilylthymidine 4 [3'-(OTBDPS)T]. 4 was synthesized via 5'-O-dimethoxytritylthymidine with t-butyldiphenylsilylchloride and deprotection of the trityl group with a solution of 2% benzoic acid in CH₂Cl₂/MeOH 7:3 to yield the 3'-silyl masked thymidine. We use the TBDPS group to protect the 5'- and 3'-positions of the dimer because these are stable against trifluoroacetic acid (TFA) used to incorporate the Fpmp group and for a better separation of the stereoisomers of 5 due to this bulky silyl group. The H-phosphonate diesters 5 were obtained as a 1:1 diastereomeric mixture with respect to the chiral phosphorus center⁸. The separation of the stereoisomers was achieved by silica gel chromatography using ethyl acetate/CH₂Cl₂ 3:1 + 0.1% acetic acid. The ³¹P-NMR chemical shifts in CDCl₃ are 7.54 ppm for the "fast"and 9.41 ppm for the "slow"-diastereomer. Diesters 5 were reacted with benzaldehyde 6 or 2nitrobenzaldehyde 7 to give the α-hydroxybenzylphosphonates 8 again in a 1:1 diastereomeric mixture with respect to the new chiral center at the α -C-atom⁹. The stereoisomers 8 were inseparable using flash chromatography and consequently the further syntheses were carried out with the diastereomeric mixtures. For the introduction of this acetalic Fpmpprotecting group 1-(2-fluorophenyl)-4-methoxy-1,2,5,6-tetrahydropyridine 9 was synthesized as described by Reese⁶. The fully blocked dimers 10 could be prepared in 70-78% yield by slightly changing the literature conditions using 3 eq. of 9 and 3 eq. of TFA in small amounts of CH₂Cl₂ as the solvent. Compound 11 is the key intermediate for the building blocks 1 and 2. Compounds 11 were isolated after deprotection of the TBDPS groups in 10 using triethylamine trihydrofluoride (NEt3•3HF; 60-70% yield) and subsequent selective 5'protection with 4,4'-dimethoxytritylchloride (70-75% yield). We used NEt3*3HF to cleave the TBDPS groups because the purification of the products was easier achieved than in the case of the tetrabutylammonium salt of the products when using TBAF in THF.

The yields of the two steps are not optimized. 1 could be prepared using the procedure of Letsinger 10 with an average loading of 30-35 μ mol/g. The phosphoamidites 2 were obtained

a) 3'-(OTBDPS)T 4, pivaloylchloride, pyridine, rt, 8 min; b) benzaldehyde 6 (or 2-nitrobenzaldehyde 7), CH₂Cl₂, NEt₃ (cat), rt, 8h; c) 1-(2-fluorophenyl)-4-methoxy-1,2,5,6-tetrahydropyridine 9, CH₂Cl₂, trifluoroacetic acid, rt, 6-18h; d) triethylamine trihydrofluoride, triethylamine, rt, 12h; e) 4,4'-dimethoxytritylchloride, DMAP, NEt₃, pyridine, 35°C, 10-15h; f) oxalylchloride, 1,2,4-triazole, CH₃CN, pyridine, rt, 1h, then AP-CPG-support (550 Å), rt, 16h; g) bis(diisopropylamino)-β-cyanoethylphosphine, CH₂Cl₂/CH₃CN (1:1), 1H-tetrazole, rt, 3h

SCHEME 1: Synthesis of the dimer building blocks 1 and 2

from 11 after reaction with bis(di*iso* propylamino)- β -cyanoethylphosphine in the presence of 1H-tetrazole.

With the dimer building blocks 1 we will be able to synthesize oligonucleotides containing one α -hydroxyphosphonate modification at the 3'-terminus. Using the phosphoamidites 2 we modify oligonucleotides at the 5'-end as well as within the backbone. Deprotection of the β -cyanoethyl groups and cleavage from the solid support using aqueous ammonia result the oligomers with the Fpmp group still at the α -hydroxy function. Acidic

cleavage of the Fpmp group will finally yield the fully unblocked, modified oligonucleotides. Furthermore, the Fpmp-protected α -hydroxyphosphonate dimers should allow the synthesis of oligonucleotides with mixed sequences containing standard base-protecting groups.

In summary, the successful synthesis of the dimer building blocks 1 and 2 demonstrates the incorporation of the Fpmp protecting group into α -hydroxybenzyl-phosphonates. The use of these building blocks in the oligonucleotide synthesis should improve the yields of protected α -hydroxyphosphonate modified oligomers. Further studies are in progress in our laboratory in order to prove their ability to act as potential *pro-oligonucleotides*. The results will be published in due course.

REFERENCES

- Uhlmann, E.; Peyman, A.; Chem. Rev. 1990, 90, 543-584; Englisch, U.; Gauss, D.; Angew. Chem. Int. Ed. Engl. 1991, 30, 613-630
- 2. Amarnath, V.; Broom, A.D.; Chem. Rev. 1977, 77, 183-217
- Iyer, R.P.; Yu, D.; Devlin, T.; Ho, N.; Agrawal, S.; Bioorg. Med. Chem. Lett. 1996, 6, 1917-1922; Tosquellas, G.; Barber, I.; Morvan, F.; Rayner, B.; Imbach, J.-L.; Bioorg. Med. Chem. Lett. 1996, 6, 457-462
- Mauritz, R.P.; Meier, C.; Uhlmann, E.; Nucleosides & Nucleotides 1997, in press; Meier, C.; Mauritz, R.P.; ibid 1995, 14, 803-804
- Meier, C.; Habel, L.; Laux, W.H.G.; De Clercq, E.; Balzarini, J.; Nucleosides & Nucleotides 1995, 14, 759-762; Meier, C.; Habel, L.; Balzarini, J.; De Clercq, E.; Liebigs Ann. 1995, 2195-2202
- 6. Reese, C.B.; Thompson, E.A.; J. Chem. Soc., Perkin Trans. 1 1988, 2881-2885
- 7. Rao, M.V.; Macfarlane, K.; Nucleosides & Nucleotides 1995, 14, 911-915
- 8. Garegg, P.J.; Regberg, T.; Stawinski, J.; Strömberg, R.; *Chemica Scripta* **1985**, 25, 280-282; Garegg, P.J.; Stawinski, J.; Strömberg, R.; *ibid* **1986**, 26, 59-62
- Meier, C.; Angew. Chem. Int. Ed. Engl. 1993, 32, 1704-1706; Kondo, K.; Ohnishi,
 N.; Takemoto, K.; Yoshida, H.; J. Org. Chem. 1992, 57, 1622-1625
- Alul, R.H.; Singman, C.N.; Zhang, G.; Letsinger, R.L.; Nucl. Acids Res. 1991, 19, 1527-1532